96 related articles for article (PubMed ID: 34790577)
1. Discovery of novel 3-(1H-pyrazol-4-yl)-1H-indazole derivatives as potent type II TRK inhibitors against acquired resistance.
Qin Q; Guo Z; Lu S; Wang X; Fu Q; Wu T; Sun Y; Liu N; Zhang H; Zhao D; Cheng M
Eur J Med Chem; 2024 Jan; 264():115953. PubMed ID: 38029466
[TBL] [Abstract][Full Text] [Related]
2. Characterization of KRC-108 as a TrkA Kinase Inhibitor with Anti-Tumor Effects.
Lee HJ; Moon Y; Choi J; Heo JD; Kim S; Nallapaneni HK; Chin YW; Lee J; Han SY
Biomol Ther (Seoul); 2022 Jul; 30(4):360-367. PubMed ID: 35264466
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and evaluate of indazolylaminoquinazoline derivatives as potent Tropomyosin receptor kinase (TRK) inhibitors.
Xu Y; Zhao W; Zhang X; Yu X; Chen Y; Wang Z; Chu Y; Zhu X; Zhang P
Bioorg Med Chem; 2024 Feb; 99():117608. PubMed ID: 38271867
[TBL] [Abstract][Full Text] [Related]
4. The anti-tumor effects of AZD4547 on ovarian cancer cells: differential responses based on c-Met and FGF19/FGFR4 expression.
Lee YY; Ryu JY; Cho YJ; Choi JY; Choi JJ; Choi CH; Sa JK; Hwang JR; Lee JW
Cancer Cell Int; 2024 Jan; 24(1):43. PubMed ID: 38273381
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of pyrazolo[3,4-
Liu N; Wang X; Fu Q; Qin Q; Wu T; Lv R; Zhao D; Cheng M
RSC Med Chem; 2023 Jan; 14(1):85-102. PubMed ID: 36760745
[TBL] [Abstract][Full Text] [Related]
6. Classification models for predicting the bioactivity of pan-TRK inhibitors and SAR analysis.
Zhao X; Kong Y; Ji Y; Xin X; Chen L; Chen G; Yu C
Mol Divers; 2023 Nov; ():. PubMed ID: 37910346
[TBL] [Abstract][Full Text] [Related]
7. Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer.
Coombes RC; Badman PD; Lozano-Kuehne JP; Liu X; Macpherson IR; Zubairi I; Baird RD; Rosenfeld N; Garcia-Corbacho J; Cresti N; Plummer R; Armstrong A; Allerton R; Landers D; Nicholas H; McLellan L; Lim A; Mouliere F; Pardo OE; Ferguson V; Seckl MJ
Nat Commun; 2023 Jan; 14(1):260. PubMed ID: 36650166
[No Abstract] [Full Text] [Related]
8. NTRK-Rearranged soft tissue neoplasms: A review of evolving diagnostic entities and algorithmic detection methods.
Surrey LF; Davis JL
Cancer Genet; 2022 Jan; 260-261():6-13. PubMed ID: 34794069
[TBL] [Abstract][Full Text] [Related]
9. Restoring
Pan W; Wang K; Li J; Li H; Cai Y; Zhang M; Wang A; Wu Y; Gao W; Weng W
Front Oncol; 2021; 11():771528. PubMed ID: 34790580
[TBL] [Abstract][Full Text] [Related]
10. Characterization of tumor microenvironment and sensitive chemotherapy drugs based on cuproptosis-related signatures in renal cell carcinoma.
Tang J; Yao F; Yao Z; Xing XL
Aging (Albany NY); 2023 Sep; 15(18):9695-9717. PubMed ID: 37728407
[TBL] [Abstract][Full Text] [Related]
11. Current Targeted Therapy for Metastatic Colorectal Cancer.
Ohishi T; Kaneko MK; Yoshida Y; Takashima A; Kato Y; Kawada M
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675216
[TBL] [Abstract][Full Text] [Related]
12. Investigation of neurotrophic tyrosine kinase receptor 1 fusions and neurotrophic tyrosine kinase receptor family expression in non-small-cell lung cancer and sensitivity to AZD7451
Tatematsu T; Sasaki H; Shimizu S; Okuda K; Shitara M; Hikosaka Y; Moriyama S; Yano M; Brown J; Fujii Y
Mol Clin Oncol; 2014 Sep; 2(5):725-730. PubMed ID: 25054037
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers.
Fuse MJ; Okada K; Oh-Hara T; Ogura H; Fujita N; Katayama R
Mol Cancer Ther; 2017 Oct; 16(10):2130-2143. PubMed ID: 28751539
[No Abstract] [Full Text] [Related]
14. Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for
Jiang T; Wang G; Liu Y; Feng L; Wang M; Liu J; Chen Y; Ouyang L
Acta Pharm Sin B; 2021 Feb; 11(2):355-372. PubMed ID: 33643817
[TBL] [Abstract][Full Text] [Related]
15. Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors.
Konicek BW; Capen AR; Credille KM; Ebert PJ; Falcon BL; Heady GL; Patel BKR; Peek VL; Stephens JR; Stewart JA; Stout SL; Timm DE; Um SL; Willard MD; Wulur IH; Zeng Y; Wang Y; Walgren RA; Betty Yan SC
Oncotarget; 2018 Mar; 9(17):13796-13806. PubMed ID: 29568395
[TBL] [Abstract][Full Text] [Related]
16. Inhibiting TRK Proteins in Clinical Cancer Therapy.
Lange AM; Lo HW
Cancers (Basel); 2018 Apr; 10(4):. PubMed ID: 29617282
[TBL] [Abstract][Full Text] [Related]
17. Anti-Tumor Activity of AZD4547 Against NTRK1 Fusion Positive Cancer Cells Through Inhibition of NTRKs.
Cho H; Kim N; Murakami T; Sim T
Front Oncol; 2021; 11():757598. PubMed ID: 34790577
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
